Integrated Protein Technologies, Inc. seeks to be the leader in developing and commercializing proteomics solutions that dramatically reduce per analysis cost. Our new instrumentation and methodologies will commoditize the measurement of peptides and intact proteins, enabling broad deployment in areas beyond basic and applied research. We believe that having precise molecular detail of proteins and peptides is key to our understanding of disease biology. The National Institutes of Health have awarded Integrated Protein Technologies with a Phase I SBIR to develop technology aimed at significantly reducing the per sample analysis cost associated with proteomics based methods. Ultimately, we hope this technology will lead to the commoditization of protein measurement and enable its use in a wide variety of applications including basic research, food safety, biologic development and more

Ibis Biosciences Inc., an Abbott Company. Led MS-based instrument development programs to transform the Ibis R&D diagnostics platform into a commercial clinical diagnostic product (PLEX-ID and IRIDICA).